Partha Chattopadhyay

About

I am passionate about the intersection of genomics, infectious diseases, and immunology, and I am committed to advancing our understanding of these critical areas. With a strong educational foundation in pharmaceutical science, I have embarked on a journey to unravel the intricate mechanisms governing gene expression in infectious diseases, focusing on long non-coding RNA, single-cell biology, and 3D genome architecture.

With an unwavering passion for genomics and its potential to transform our understanding of infectious diseases, I envision a future where our research leads to the development of targeted therapies and personalized medicine approaches. By pushing the boundaries of genomics, I aspire to make a meaningful impact on global health and disease management.

Employment

• University of Cambridge Research Associate
  2025 - Present
• CSIR Institute of Genomics & Integrative Biology Senior Research Fellow
  2022 - 2024
• CSIR-Institute of Genomics and Integrative Biology Junior Research Fellow
  2020 - 2022

Education

• Academy of Scientific and Innovative Research Ph.D.
  2020 - 2024
• National Institute of Pharmaceutical Education and Research Guwahati M.S (Pharm)
  2018 - 2020
• Bengal School of Technology B.Pharm
  2014 - 2018

Projects & Funding

Projects & funding information is unavailable.

Publications (30)

• Transcriptional landscapes of dengue patients reveal associations between HERV activity and disease severity
  NAR Molecular Medicine 2026 DOI: 10.1093/narmme/ugag030
  +Save
• Cell-specific housekeeping role of lncRNAs in COVID-19-infected and recovered patients
  NAR Genomics and Bioinformatics 2024 DOI: 10.1093/nargab/lqae023
  +Save
• SARS-CoV-2 infection severity and mortality is modulated by repeat-mediated regulation of alternative splicing
  Microbiology Spectrum 2023 DOI: 10.1128/spectrum.01351-23
  +Save
• BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies
  PLOS Pathogens 2023 DOI: 10.1371/journal.ppat.1011196
  +Save
• A Tour-d’Horizon of microbiota therapeutics for metabolic disorders
  Microbiome Therapeutics 2023 DOI: 10.1016/b978-0-323-99336-4.00006-9
  +Save
• Experimental repertoire to elucidate the functional landscape of host–pathogen interactome
  Genomic Surveillance and Pandemic Preparedness 2023 DOI: 10.1016/b978-0-443-18769-8.00003-9
  +Save
• Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?
  Frontiers in Microbiology 2022 DOI: 10.3389/fmicb.2022.763169
  +Save
• COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits
  PLOS ONE 2022 DOI: 10.1371/journal.pone.0264785
  +Save
• Infection outcome needs two to tango: human host and the pathogen
  Briefings in Functional Genomics 2022 DOI: 10.1093/bfgp/elab037
  +Save
• Human‐host transcriptomic analysis reveals unique early innate immune responses in different sub‐phenotypes of COVID‐19
  Clinical and Translational Medicine 2022 DOI: 10.1002/ctm2.856
  +Save